JamesRalphRigasMDFACP

Oncology • Hanover, NH

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, Geisel School of Medicine at Dartmouth

Join to view full profile

Dr. Rigas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rigas' full profile

Already have an account?

Office
3 Mulherrin Farm Rd
Hanover, NH 03755

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1990
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1984 - 1988
MCP-Hahnemann College of MedicineClass of 1984

Certifications & Licensure

NH State Medical License 1995 - 2021
VT State Medical License 1995 - 2004

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer Start of enrollment: 1998 Nov 01
Terminated
Phase 1, Phase 2
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2005 May 01
Completed
Phase 3
A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer Start of enrollment: 2001 Aug 01
Terminated
Phase 1, Phase 2
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 4
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 1
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin Start of enrollment: 2011 Jan 16
Completed
Phase 3
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer Start of enrollment: 2010 Jul 01
Completed
Join now to see all

Publications & Presentations

PubMed

2 citations
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark.
Elizabeth Hedgeman, Mette Nørgaard, Tapashi Dalvi, Lars Pedersen, Hanh Hansen
Cancer Epidemiology. 2021-07-01
1 citations
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.
Matthew B. Schabath, Tapashi Dalvi, Hongyue A Dai, Alan Crim, Anita Midha
Cancer Management and Research. 2019-11-07
42 citations
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Filippo de Marinis, Yi-Long Wu, Gilberto de Castro, Gee-Chen Chang, Yuh Min Chen
Future Oncology. 2019-07-24

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
International Association for the Study of Lung Cancer
Member